selonsertib   Click here for help

GtoPdb Ligand ID: 9040

Synonyms: GS-4997
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Selonsertib is an orally bioavailable apoptosis signal-regulating kinase 1 (ASK1= mitogen-activated protein kinase kinase kinase 5, MAP3K5) inhibitor being investigated for its anti-fibrotic activity. It is compound I in patent US8742126 [2]. Development as a treatment for nonalcoholic steatohepatitis (NASH) was unsuccessful.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 90
Molecular weight 445.2
XLogP 5.68
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES O=C(c1cc(c(cc1F)C)n1cnc(c1)C1CC1)Nc1cccc(n1)c1nncn1C(C)C
Isomeric SMILES O=C(c1cc(c(cc1F)C)n1cnc(c1)C1CC1)Nc1cccc(n1)c1nncn1C(C)C
InChI InChI=1S/C24H24FN7O/c1-14(2)32-13-27-30-23(32)19-5-4-6-22(28-19)29-24(33)17-10-21(15(3)9-18(17)25)31-11-20(26-12-31)16-7-8-16/h4-6,9-14,16H,7-8H2,1-3H3,(H,28,29,33)
No information available.
Summary of Clinical Use Click here for help
Selonsertib is being evaluated in Phase 2 clinical trial, alone or in combination with simtuzumab, in adult patients with nonalcoholic steatohepatitis (NASH) and stage F2-F3 fibrosis (see NCT02466516).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02466516 Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3 Phase 2 Interventional Gilead Sciences